Pediatrics Archive — Page 1 of 32

Nicole Sibol
October 8, 2026

Nicole Sibol named inaugural Vice President and Chief Pediatric Enterprise Strategy Officer

She will help drive strategic growth and shape the future of pediatric care and programming for Monroe Carell Jr. Children’s Hospital at Vanderbilt.

Heart transplant patient Aleah (Sissy) Keasling.
October 7, 2026

First-of-its-kind heart transplant gives Sissy a second chance

The novel technique could help increase the number of donor hearts available to children awaiting transplant and reduce the time they spend waiting.

Vanderbilt Health performed a record number of solid organ transplants in fiscal year 2026 — 981 lifesaving procedures among its adult and pediatric programs. (photo by Erin O. Smith)
October 7, 2026

Monroe Carell Jr. Children’s Hospital at Vanderbilt leads breakthrough heart recovery method for pediatric transplants

Surgeons used the novel technique known as REUP (rapid recovery with extended ultraoxygenated preservation). Since then, five more children were saved successfully.

Ian M. Burr, MD, PhD
October 7, 2026

Vanderbilt mourns the loss of pediatrics leader and children’s health advocate Ian Burr

Former Pediatrics department chair and pediatric endocrinologist helped shape generations of children’s health care, research and education at Vanderbilt.

Celebrating the opening of the new Milk Drop Depot location are, from left, Jessica Esquilin, MA, Adebukola Ajagunna, MD, Pam Bush, APRN, Bailey Leavell, APRN, Charley Oxford, PSS, and Tabitha Wheeler, PSS.
September 30, 2026

Vanderbilt Pediatric Associates Hopkinsville and Mothers’ Milk Bank Southeast open Milk Drop Depot in Kentucky

The processed donor milk is distributed to neonatal intensive care units and mothers in need across Tennessee, Kentucky and Georgia, helping provide lifesaving nutrition for premature and medically fragile infants.

September 28, 2026

California firm licenses ‘potent’ anti-measles antibodies from Vanderbilt Health for development, clinical testing

The human monoclonal antibodies were isolated from two individuals who had been infected by measles. Further development and clinical testing could lead to the first monoclonal antibody therapy against the highly infectious respiratory virus.